Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, reported unaudited financial results for the third quarter ended Dec. 31, 2025. The company highlighted continued progress across its HLP003 Phase 3 program for major depressive disorder and HLP004 Phase 2 program for generalized anxiety disorder, along with a completed leadership transition and corporate rebranding.
Helus Pharma ended the quarter with $195.1 million in cash and reported a net loss of $42.7 million, as operating expenses increased to support advancing clinical activities. Management emphasized its strengthened balance sheet, expanding intellectual property portfolio, and upcoming clinical data milestones in 2026. The company's ability to fund its ongoing trials without near-term financing concerns is a critical factor for investors, given the high costs associated with late-stage clinical development.
The Phase 3 program for HLP003, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, targets major depressive disorder as an adjunctive treatment. This designation underscores the potential of HLP003 to address a significant unmet need in mental health, where many patients do not respond adequately to existing therapies. The Phase 2 program for HLP004 focuses on generalized anxiety disorder, another area with limited treatment options. Positive data from these trials could position Helus Pharma as a leader in the emerging field of serotonergic agonists, which aim to promote neuroplasticity and provide durable improvements in mental health.
The company's proprietary novel serotonergic agonists (NSAs) are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. Helus Pharma aims to improve the treatment landscape for depression, anxiety, and other mental health conditions. With an extensive research portfolio of investigational NSAs, the company is building a pipeline that could address multiple indications. The successful completion of the leadership transition and rebranding to Helus Pharma from Cybin Inc. signals a strategic focus on commercializing its lead assets.
For more details on the financial results, the full press release is available at https://ibn.fm/VigPf. Investors can also access the latest news and updates relating to HELP at the company's newsroom https://ibn.fm/HELP.
The implications of this announcement are significant for the mental health treatment landscape. If HLP003 and HLP004 succeed in clinical trials, they could offer new options for patients with major depressive disorder and generalized anxiety disorder who have not found relief with current treatments. The Breakthrough Therapy Designation for HLP003 indicates FDA recognition of its potential, which could accelerate its path to market. For Helus Pharma, advancing these programs is crucial for transitioning from a clinical-stage company to a commercial entity, and the upcoming data milestones in 2026 will be key catalysts for the stock and the broader biotech sector.
